SCHEDULE: Beta Bionics: Major Stakeholders Disclose Shareholdings

Multiple entities and individuals associated with Farallon Capital Management have filed Schedule 13G amendments, collectively reporting significant beneficial ownership of Beta Bionics, Inc. common stock.

Summary

• This filing is an amendment to a Schedule 13G, indicating changes in beneficial ownership of Beta Bionics, Inc. common stock.
• Several entities, including Zone Healthcare Holdings, LLC, and various Farallon Capital funds and related entities, are listed as reporting persons.
• Individual managing members and senior managing members of Farallon Capital Management, L.L.C. and related general partners are also listed as reporting persons.
• The filing details the number of shares beneficially owned and the percentage of the class represented by these holdings for each reporting person.
• The reporting date for this amendment is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not contain operational or financial performance information.

Future Outlook

This filing does not contain forward-looking statements or guidance. It is a disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors and significant stakeholders, indicating their investment positions in publicly traded companies. The aggregation of holdings by entities and individuals associated with Farallon Capital Management suggests a coordinated investment strategy or significant influence over Beta Bionics.

Stakeholder Impact

• Shareholders: The filing provides transparency on significant ownership stakes, which can influence market perception and trading activity.

Key Dates

Keywords

Schedule 13G, Beta Bionics, Beneficial Ownership, SEC Filing, Farallon Capital Management, Investment Holdings, Common Stock